ElevateBio Acquires Life Edit Therapeutics from AgBiome Delta

Repligen Acquires BioLife Solutions for $1.5 Billion

July 23, 2026

Healthcare Services

Repligen has entered into a definitive agreement to acquire BioLife Solutions in a cash-and-stock transaction with an enterprise value of approximately $1.5 billion. The deal is expected to close in the fourth quarter of 2026, subject to BioLife shareholder approval and regulatory clearances.

Eli Lilly Acquires Engage Biologics

May 23, 2026

Biotechnology

Eli Lilly and Company has acquired Engage Biologics in a deal valued at up to $202 million in cash, including an upfront payment and milestone-based payments. The acquisition is intended to strengthen Lilly’s genetic medicines capabilities by integrating Engage’s non-viral DNA delivery Tethosome platform with Lilly’s broader development portfolio.

Eclipsebio Acquires Terrain Bio

January 29, 2026

Biotechnology

Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.

OmniActive Health Technologies Acquires ENovate Biolife

November 4, 2024

Food & Beverage

OmniActive Health Technologies has acquired ENovate Biolife to expand its portfolio of clinically validated botanical and specialty active ingredients for dietary supplements, functional foods and sports nutrition. The acquisition strengthens OmniActive's R&D, clinical and commercial capabilities and aims to accelerate global distribution of ENovate's ingredients such as Muvz, RedNite and Oxyjun.

Tome Biosciences Acquires Replace Therapeutics

January 5, 2024

Biotechnology

Tome Biosciences has acquired Replace Therapeutics in a merger valued at $65 million in up-front and near-term milestones and up to $185 million total through a mix of cash and stock. Replace will become a wholly owned subsidiary of Tome, adding its ligase-mediated programmable genomic integration (L-PGI) technology to complement Tome's large-DNA integrase-mediated PGI platform to expand the company's gene‑editing capabilities.

Intellia Therapeutics Acquires Rewrite Therapeutics

February 3, 2022

Biotechnology

Intellia Therapeutics has acquired Rewrite Therapeutics, a UC Berkeley–spawned startup developing DNA-writing genome editing technologies. The deal includes $45 million upfront and up to $155 million in research and regulatory milestones, expanding Intellia's in-house editing capabilities to potentially enable new precision editing strategies.